The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
The company will start three phase 3 trials of its G12D project this year.
But PFS data are lacking, and there are questions about first and second-line plans.
But the company still has a lot to prove with ERAS-0015.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
The company secures funding to push its lead candidate towards US approval.
